RT Journal Article
SR Electronic
T1 SARS-CoV-2 RNA screening in routine pathology specimens
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.25.21250082
DO 10.1101/2021.01.25.21250082
A1 Stillfried, Saskia von
A1 Villwock, Sophia
A1 Bülow, Roman D.
A1 Djudjaj, Sonja
A1 Buhl, Eva M.
A1 Maurer, Angela
A1 Ortiz-Brüchle, Nadina
A1 Celec, Peter
A1 Klinkhammer, Barbara M.
A1 Wong, Dickson W.L.
A1 Cacchi, Claudio
A1 Braunschweig, Till
A1 Knüchel-Clarke, Ruth
A1 Dahl, Edgar
A1 Boor, Peter
YR 2021
UL http://medrxiv.org/content/early/2021/01/26/2021.01.25.21250082.abstract
AB Virus detection methods are important to cope with the SARS-CoV-2 pandemics. Apart from the lung, SARS-CoV-2 was detected in multiple organs in severe cases. Less is known on organ tropism in patients developing mild or no symptoms, and some of such patients might be missed in symptom-indicated swab testing.Here we tested and validated several approaches and selected the most reliable RT-PCR protocol for the detection of SARS-CoV-2 RNA in patients’ routine diagnostic formalin-fixed and paraffin-embedded (FFPE) specimens available in pathology, to assess a) organ tropism in samples from COVID-19-positive patients, b) unrecognized cases in selected tissues from negative or not-tested patients during a pandemic peak, and c) retrospectively, pre-pandemic lung samples.We identified SARS-CoV-2 RNA in four samples from confirmed COVID-19 patients, in two gastric biopsies, one colon resection, and one pleural effusion specimen, while all other specimens, particularly from patients with mild COVID-19 disease course, were negative. In the pandemic peak cohort, we identified one previously unrecognized COVID-19 case in tonsillectomy samples. All pre-pandemic lung samples were negative.In conclusion, SARS-CoV-2 RNA detection in FFPE pathology specimens can potentially improve surveillance of COVID-19, allow retrospective studies, and advance our understanding of SARS-CoV-2 organ tropism and effects.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the German Registry of COVID-19 Autopsies (www.DeRegCOVID.ukaachen.de), funded by the Federal Ministry of Health (ZMVI1-2520COR201), by the Federal Ministry of Education and Research within the framework of the network of university medicine (DEFEAT PANDEMIcs, 01KX2021 and STOP-FSGS-01GM1901A), the German Research Foundation (DFG; SFB/TRR57, SFB/TRR219, BO3755/3-1, BO3755/9-1, and BO3755/13-1), and the RWTH START-Program (125/17).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was given ethical approval by the ethics committee at the medical faculty of RWTH Aachen University (EK 304/20, EK 119/20, and EK 092/20).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analysed during the current study are not publicly available due to protect study participant privacy, but are available from the corresponding author on reasonable request.